Should You Buy Bristol Myers Squibb Stock At Today’s Discount?
Today’s big story: Will 2027 Be A 2022 Repeat For Stocks?
Bristol Myers Squibb (BMY) stock trades at 12.9 times earnings, against 21.1 for the median S&P 500 company. The current share price appears to assume profit will shrink as older drugs face generic copies. This makes the stock either a good business on sale or a fair price for one about to earn less. So are Bristol Myers Squibb’s newer drugs growing fast enough to fill that hole?
Bristol Myers Squibb’s P/E of 12.9 looks cheap, but a cheap stock can stay cheap for a long time. If you are holding cash until this plays out, that money can still earn something while it waits. The Trefis Income Solution pays a dividend yield about 3 times the S&P 500’s, from 50 companies that have paid dividends for at least 10 years in a row. See what it pays.

Bristol Myers Squibb’s Newer Drugs Are Growing Fast
So far, the growth is strong. Management said sales of its newer medicines rose 12% to $7.7 billion in fiscal Q3 2026. Total revenue rose 7% to $13.1 billion, so the newer drugs grew faster than the company as a whole.
Bristol Myers Squibb now has eight of these newer medicines, each selling at a pace of more than $1 billion a year. The business also generates cash while that growth builds. Its free cash flow equals 7.8% of the stock’s market value.
Even so, the overall company is growing slowly. Total revenue rose 4.2% over the four quarters ended September 30, 2026, against 8.8% for the median S&P 500 company.
Is Bristol Myers Squibb Earning More Than Usual?
Earnings are up sharply, and margins are at a high. The company posted an operating margin of 29.2% over the four quarters ended September 30, 2026. That is the highest of the 40 quarter ends since fiscal Q4 2016. The average over the last three twelve-month periods was 22.8%.
Net profit has swung even more. Bristol Myers Squibb lost $7.26 billion over the four quarters ended September 30, 2024. Its net margin has since climbed to 18.5%. That compares to a three-period average of 5.2%. The earnings underpinning today’s low P/E therefore represent the best results of the past three years, rather than a typical year.
Cash moved in the opposite direction. Cash from operations fell to $10.7 billion over the past four quarters, dropping from $16.6 billion a year earlier.
Management Expects Bristol Myers Squibb’s Eliquis Sales To Shrink
The current P/E rests on past earnings. But Bristol Myers Squibb has already said its largest drug, Eliquis, will sell less in 2027. Eliquis generated 30.0% of fiscal 2025 revenue. Management said sales of the drug will take a hit in fiscal Q4 2026 when its exclusive rights in Europe expire. The company expects a $1.5 billion to $2 billion step down in Eliquis in 2027.
Sales of an older drug can fall fast. Revlimid sales fell 48.9% to $2.95 billion in fiscal 2025.
Management is countering with lower costs and more growth. The company says it is on track for $2 billion of efficiencies by the end of 2027. It also raised its fiscal 2026 revenue forecast to $49.8 billion to $50.3 billion, up from $49.5 billion. If the newer drugs fall short, the earnings supporting today’s P/E would shrink, leaving the stock less cheap than it appears.
What A Buyer At This Price Is Betting On
A buyer at today’s P/E is not betting that the market has misjudged the business. The bet is that newer drugs and the planned savings can cover the Eliquis step down. The newer drugs are growing faster than the company so far. In fiscal Q3 2026 alone, their sales rose about $0.8 billion from a year earlier. The company expects Eliquis to step down $1.5 billion to $2 billion over all of 2027. Profit is less certain. Margins sit at a high that may not last, and cash from operations fell.
Bristol Myers Squibb is expected to report its fiscal Q4 2026 results in February 2027. That report will give the full-year operating margin. It will also show how much the end of Eliquis’s exclusive rights in Europe cut into fourth-quarter sales.
Eliquis alone brought in 30.0% of Bristol Myers Squibb’s fiscal 2025 revenue. That is a lot resting on one drug if this stock is a big part of your savings. It helps to decide now how and when you would step out.
Too Much Riding On One Stock?
If Bristol Myers Squibb is a big part of your wealth, so are its risk and its tax bill. What’s your exit plan? Our partner advisory firm offers a free 30-minute strategy review covering a floor under losses and a lower-tax way out.
Spot an error or want more like this? Tell us in 10 seconds.